Intravenous immunoglobulin (IVIg) modulates the expansion of Vβ3+ and Vβ17+ T cells induced by staphylococcal enterotoxin B superantigen in vitro

Scandinavian Journal of Immunology

Volumn 43, Issue 3, 1996, Pages 277-282

  Baudet, V ^a   Hurez, V ^a   Lapeyre, C ^b   Kaveri, S V ^a,c   Kazatchkine, M D ^a  

^a INSERM   (France)

^b Lab Ctrl d'Hyg Alimentaire   (France)

^c HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN;

ADULT; ARTICLE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0029979481     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1996.d01-36.x     Document Type: Article

References (28)

1. Buckley RH, Schiff RI. The use of intravenous immunoglobulin in immunodeficiency diseases. N Engl J Med 1991;325:110-17.
2. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-16.
3. Mouthon L, Kaveri SV, Kazatchkine MD. Immune modulating effects of intravenous immunoglobulins (IVIg) in autoimmune diseases. Tranfus Sci 1994;15:393-408.
4. Forsgren S, Andersson A, Hillorn V, Soderstrom A, Holmberg D. Immunoglobulin-mediated prevention of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Scand J Immunol 1991;34:445-51.
5. Rossi F, Bellon B, Vial MC, Druet P, Kazatchkine MD. Beneficial effect of human therapeutic intravenous immunoglobulins (IVIg) in mercuric-chloride-induced autoimmune disease of Brown-Norway rats. Clin Exp Immunol 1991;84:129-33.
6. Saoudi A, Hurez V, de Kozak Y et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993;5:1559-67.
7. Hentati B, Sato MN, Payelle-Brogard B, Avrameas S, Ternynck T. Beneficial effect of polyclonal immunoglobulins from malaria-infected Balb/c mice on lupus-like syndrome of (NZB x NZW)F1 mice. Eur J Immunol 1994;24:8-15.
8. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med 1982;306:1254-8.
9. Kazatchkine MD, Dietrich G, Hurez V et al. V Region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 1994;139:79-107.
10. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989;143: 4104-9.
11. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schlutter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β chain. Proc Natl Acad Sci USA 1992;89:3325-9.
12. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993;92:369-72.
13. Hurez V, Kaveri SV, Mouhoub A et al. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (Intravenous immunoglobulin, IVIg). Therap Immunol 1994;1:269-78.
14. Andersson UG, Bjork L, Skansén-Saphir U, Andersson JP. Down-regulation of cytokine production and IL-2 receptor expression by pooled human IgG. Immunology 1993;79:211-16.
15. Ruiz-de-Souza V, Carreno MP, Kaveri SV, Cavaillon JM, Kazatchkine MD, Haeffner-Cavaillon N. Selective induction of IL-Ira and IL-8 in human monocytes by normal polyspecific immunoglobulin G for therapeutic use (IVIg). Eur J Immunol 1995;25:1267-73.
16. Toyoda M, Zhang X, Petrosian A, Galera OA, Wang S, Jordan SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994;14:178-88.
17. Abe J, Kotzin BL, Meissner C et al. Characterization of T Cell Repertoire Changes in Acute Kawasaki Disease. J Exp Med 1993;177:791-6.
18. Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous gammaglobulin. N Engl J Med 1986;315:341-7.
19. Drake CG, Kotzin BL. Superantigens: Biology, Immunology, Potential Role in Disease. J Clin Immunol 1992;12:149-62.
20. Leung DYM, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;342: 1385-8.
21. Debré M, Bonnet MC, Fridman WH et al. Infusion of Fcγ fragments for the treatment of children with acute immune thrombocytopenic purpura. Lancet 1993;342:945-9.
22. Lapeyre C, Janin F, Kaveri SV. Indirect double sandwich ELISA using monoclonal antibodies for detection of staphylococcal to enterotoxins A, B, C1 and D in food samples. Food Microbiology 1987;5:25-31.
23. Marrack P, Kappler J. The Staphylococcal Enterotoxins and their relatives. Science 1990;248:705-11.
24. Diu, A, Romagné F, Genevée C et al. Fine specificity of monoclonal antibodies directed at human T cell receptor variable regions: comparison with oligonucleotide-driven amplification for evaluation of Vβ expression. Eur J Immunol 1993;23:1422-9.
25. Takei S, Arora Y, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993;91:602-7.
26. Blascvyk R, Westhoff U, Grossewilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341(8848):789-90.
27. Amran A, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994;73: 180-6.
28. Van Schaik IN, Lundkvist I, Vermeulen M, Brand A, Polyvalent Immunoglobulin for Intravenous Use Interferes with cell proliferation in vitro. J Clin Immunol 1992;12:325-34.